Rybelsus, known by its active ingredient semaglutide, is a revolutionary oral medication specifically designed for the treatment of type 2 diabetes. A glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, mirrors the function of the body’s incretin hormones. This simulation results in an increased release of insulin during meal times, a reduction in the rate of gastric emptying, and an overall decrease in appetite. By carrying out these functions, Rybelsus effectively aids in the regulation of blood glucose levels.